Able to comprehend and provide a signed written informed consent, which must be obtained prior to initiation of screening study procedures;
Willing and able to comply with all study requirements;
Presents at a study site needing or wanting PrEP for HIV prevention as determined by local clinical practice guidelines and institutional protocols, including new PrEP users (PrEP naïve) and current or former users of oral (emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada®; F/TDF) or emtricitabine/tenofovir alafenamide (coformulated; Descovy®; F/TAF)) or injectable (LEN or cabotegravir (CAB)) PrEP who indicate interest in discussing PrEP methods that they are clinically eligible to receive;
Eligible for LEN PrEP per standard of care procedures, for example, being HIV-1 negative at screening using a Food and Drug Administration (FDA) approved/cleared test for diagnosis of acute or primary HIV-1 infection;
After PrEP counseling to learn about the advantages and disadvantages of various PrEP methods:
1. Selects LEN PrEP as their chosen PrEP method; OR,
2. Selects a different PrEP method or chooses not to start or continue PrEP.
You may not be if
Any other indication not already listed above that would make the participant ineligible for LEN PrEP at enrollment according to local guidelines, organizational protocols, US Prescribing Information (USPI) for the PrEP product, and/or Center for Disease and Control (CDC) guidance.
Clareo Health | Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
